Case Study and Clinical Highlight: Diagnosis of Pulmonary Involvement in Systemic Sclerosis

Case Study and Clinical Highlight: Diagnosis of Pulmonary Involvement in Systemic Sclerosis

Engage in this case study to test your diagnostic ability to differentiate pulmonary hypertension in the setting of systemic sclerosis.

Latest News

PAH in Systemic Sclerosis Increases Risk for Early Mortality

PAH in Systemic Sclerosis Increases Risk for Early Mortality

The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Smoking Not Associated With Systemic Sclerosis-Specific Cutaneous, Pulmonary Manifestations

Smoking Not Associated With Systemic Sclerosis-Specific Cutaneous, Pulmonary Manifestations

Smoking status in patients with systemic sclerosis was not significantly associated with systemic sclerosis-specific cutaneous or pulmonary changes.

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

Recent evidence suggests that systemic sclerosis and SLE in pulmonary arterial hypertension should be considered separate diseases.

LPA1 Receptor Antagonist SAR100842 Safe, Well Tolerated in Systemic Sclerosis

LPA1 Receptor Antagonist SAR100842 Safe, Well Tolerated in Systemic Sclerosis

The investigational drug SAR100842 was safe, moderately effective, and well tolerated in patients with early diffuse cutaneous systemic sclerosis.

Expert Insight: Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis

Expert Insight: Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis

Although pulmonary arterial hypertension occurs in a minority of patients with systemic sclerosis, clinicians must be attentive to it, as it can emerge at any point over the course of the disease.

Scleroderma Phenotype, Autoantibodies May Identify Patients at Risk for Cancer

Scleroderma Phenotype, Autoantibodies May Identify Patients at Risk for Cancer

Stratification by clinical features and autoantibody response identify scleroderma subgroups with distinct risks for cancer.

Independent Predictors of VTE Identified in Systemic Sclerosis

Independent Predictors of VTE Identified in Systemic Sclerosis

Researchers evaluated the prevalence, risk factors, and effect of venous thromboembolism on survival in systemic sclerosis.

Predicting Skin Score Changes in Early Diffuse Systemic Sclerosis

Predicting Skin Score Changes in Early Diffuse Systemic Sclerosis

Two predictive models for progressive skin thickening in patients with early diffuse cutaneous systemic sclerosis were developed to use in clinical practice and to improve recruitment in clinical trials.

Social Anxiety in Systemic Sclerosis: Comparing Patient Assessment Tools

Social Anxiety in Systemic Sclerosis: Comparing Patient Assessment Tools

Investigators assessed 3 versions of the Brief Fear of Negative Evaluation scale in patients with systemic sclerosis.

Sign Up for Free e-newsletters